HR
CNCE

Howe & Rusling’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Howe & Rusling’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55
Closed -$1K – 966
2018
Q1 		$1K Buy
55
+15
+38% +$334 ﹤0.01% 906
2017
Q4 		$1K Buy
+40
New +$805 ﹤0.01% 814

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Howe & Rusling's CNCE Position: Q2 2018 in Review

Howe & Rusling sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 55 shares — an estimated $1K sold.

Howe & Rusling first reported a position in CNCE in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

  • Howe & Rusling reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Howe & Rusling sold 55 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1K.
  • Howe & Rusling first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
  • Howe & Rusling's Concert Pharmaceuticals, Inc. position peaked at $1K in Q1 2018.
  • 120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Howe & Rusling's 13F filing for Q2 2018, filed 31 Jul 2018.